Weil, who was OpenAI’s chief product officer, and medicinal chemist Reisberg unpack the investment memo for their robotics-first research lab with Lightspeed’s Guru Chahal. The conversation covers how drug discovery currently runs through Chinese contract research organisations, why domestic alternatives cost several times more, and how Warp plans to start with instrumented chemists and automate one step at a time.
Why Warp Sciences thinks chemistry needs robot lab hands
Kevin Weil and Sol Reisberg explain the engineering bottleneck that pushed them to build an automated lab.
